Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-time-in-human, Randomised, Double-blind, Placebo-controlled, Parallel-group Study in Healthy Volunteers and Patients With Asthma to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending and Repeat Doses of PIN201104

Trial Profile

A First-time-in-human, Randomised, Double-blind, Placebo-controlled, Parallel-group Study in Healthy Volunteers and Patients With Asthma to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending and Repeat Doses of PIN201104

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PIN 201104 (Primary) ; PIN 201104 (Primary)
  • Indications Asthma
  • Focus Adverse reactions; First in man
  • Sponsors Immune Regulation; Peptinnovate
  • Most Recent Events

    • 26 Nov 2018 Results presented in an Immune Regulation Media Release.
    • 22 Nov 2018 According to an Immune Regulation media release, Peptinnovate acquired Immune Regulation Ltd. earlier this year and today the company announced that that it has changed its corporate name from Peptinnovate to Immune Regulation with immediate effect.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top